Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
Clinical trial NCT05616221 · COMPLETED
Trial details
- NCT number
- NCT05616221
- Sponsor
- Armata Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-10
- Primary completion
- 2024-07-17
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.